Company profile for Halia Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

At Halia Therapeutics we are discovering and developing novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases. We do this by advancing innovative medicines that target the immune system's response to resolve chronic inflammation and eliminate the damage caused by aberrantly activated immune responses.We use an innovative approach to drug discovery by translating advances in the ...
At Halia Therapeutics we are discovering and developing novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases. We do this by advancing innovative medicines that target the immune system's response to resolve chronic inflammation and eliminate the damage caused by aberrantly activated immune responses.We use an innovative approach to drug discovery by translating advances in the understanding of the importance of inflammation in human pathologies such as cancer and neurodegenerative diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1865 W 2100 S, Suite 100 Salt Lake City, Utah 84119
Telephone
Telephone
(385) 355-4315
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/halia-therapeutics-to-present-groundbreaking-data-on-novel-allosteric-nek7-inhibitor-ofirnoflast-at-the-2025-american-society-of-hematology-annual-meeting-302609730.html

PR NEWSWIRE
10 Nov 2025

https://www.prnewswire.com/news-releases/ofirnoflast-ht-6184-receives-orphan-drug-designation-from-us-fda-for-myelodysplastic-syndromes-302592239.html

PR NEWSWIRE
23 Oct 2025

https://www.prnewswire.com/news-releases/halia-therapeutics-strengthens-global-genomics-leadership-with-appointment-of-paul-jones-as-chief-strategy-officer--gm-international-markets-302575149.html

PR NEWSWIRE
06 Oct 2025

https://www.prnewswire.com/news-releases/halia-therapeutics-to-participate-in-the-morgan-stanley-23rd-annual-global-healthcare-conference-302546054.html

PR NEWSWIRE
04 Sep 2025

https://www.prnewswire.com/news-releases/halia-therapeutics-completes-first-in-human-phase-1-study-of-ht-4253-a-novel-lrrk2-inhibitor-targeting-neuroinflammation-302482102.html

PR NEWSWIRE
16 Jun 2025

https://www.prnewswire.com/news-releases/halia-therapeutics-awarded-novo-nordisk-golden-ticket-to-advance-obesity-and-inflammation-research-302396740.html

PR NEWSWIRE
11 Mar 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty